Search Results - "Jabbour, Elias J"

Adult Acute Lymphoblastic Leukemia by Paul, Shilpa, PharmD, BCOP, Kantarjian, Hagop, MD, Jabbour, Elias J., MD

“…Abstract Conventional cytotoxic chemotherapy used to treat acute lymphoblastic leukemia (ALL) results in high cure rates in pediatric patients but is…”
Get full text

Acute lymphoblastic leukemia in adolescents and young adults by Rytting, Michael E., Jabbour, Elias J., O'Brien, Susan M., Kantarjian, Hagop M.

“…Acute lymphoblastic leukemia (ALL) in the adolescent and young adult (AYA) population is a difficult clinical problem. The AYA population, generally regarded…”
Get full text

The cure of leukemia through the optimist's prism by Kantarjian, Hagop M., Jain, Nitin, Garcia‐Manero, Guillermo, Welch, Mary Alma, Ravandi, Farhad, Wierda, William G., Jabbour, Elias J.

“…Progress is occurring at a dizzying rate across all leukemias. Since the authors' review of the topic in Cancer in 2018, numerous discoveries have been made…”
Get full text

Patient‐reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia by Kantarjian, Hagop M., Su, Yun, Jabbour, Elias J., Bhattacharyya, Helen, Yan, Eric, Cappelleri, Joseph C., Marks, David I.

“…BACKGROUND Inotuzumab ozogamicin (InO), an anti‐CD22 antibody‐calicheamicin conjugate, demonstrated superior clinical activity versus standard‐of‐care (SOC)…”
Get full text

Genomic and Immunophenotypic Landscape of Aggressive NK-Cell Leukemia by El Hussein, Siba, Patel, Keyur P., Fang, Hong, Thakral, Beenu, Loghavi, Sanam, Kanagal-Shamanna, Rashmi, Konoplev, Sergej, Jabbour, Elias J., Medeiros, L. Jeffrey, Khoury, Joseph D.

“…Aggressive natural killer-cell leukemia (ANKL) is a rare, lethal disease with pathologic features that are underdescribed in the literature, particularly in…”
Get full text

A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome by Swaminathan, Mahesh, Kantarjian, Hagop M, Levis, Mark, Guerra, Veronica, Borthakur, Gautam, Alvarado, Yesid, DiNardo, Courtney D, Kadia, Tapan, Garcia-Manero, Guillermo, Ohanian, Maro, Daver, Naval, Konopleva, Marina, Pemmaraju, Naveen, Ferrajoli, Alessandra, Andreeff, Michael, Jain, Nitin, Estrov, Zeev, Jabbour, Elias J, Wierda, William G, Pierce, Sherry, Pinsoy, Maria Rhona, Xiao, Lianchun, Ravandi, Farhad, Cortes, Jorge E

“…FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) mutation in acute myeloid leukemia (AML) is associated with poor prognosis. We hypothesized…”
Get full text

Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia by Maiti, Abhishek, DiNardo, Courtney D., Daver, Naval G., Rausch, Caitlin R., Ravandi, Farhad, Kadia, Tapan M., Pemmaraju, Naveen, Borthakur, Gautam, Bose, Prithviraj, Issa, Ghayas C., Short, Nicholas J., Yilmaz, Musa, Montalban-Bravo, Guillermo, Ferrajoli, Alessandra, Jabbour, Elias J., Jain, Nitin, Ohanian, Maro, Takahashi, Koichi, Thompson, Philip A., Loghavi, Sanam, Montalbano, Kathryn S., Pierce, Sherry, Wierda, William G., Kantarjian, Hagop M., Konopleva, Marina Y.

Get full text

Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia by Kimura, Shunsuke, Montefiori, Lindsey, Iacobucci, Ilaria, Zhao, Yaqi, Gao, Qingsong, Paietta, Elisabeth M., Haferlach, Claudia, Laird, A. Douglas, Mead, Paul E., Gu, Zhaohui, Stock, Wendy, Litzow, Mark, Rowe, Jacob M., Luger, Selina M., Hunger, Stephen P., Ryland, Georgina L., Schmidt, Breon, Ekert, Paul G., Oshlack, Alicia, Grimmond, Sean M., Rehn, Jacqueline, Breen, James, Yeung, David, White, Deborah L., Aldoss, Ibrahim, Jabbour, Elias J., Pui, Ching-Hon, Meggendorfer, Manja, Walter, Wencke, Kern, Wolfgang, Haferlach, Torsten, Brady, Samuel, Zhang, Jinghui, Roberts, Kathryn G., Blombery, Piers, Mullighan, Charles G.

“…Transcriptome sequencing has identified multiple subtypes of B-progenitor acute lymphoblastic leukemia (B-ALL) of prognostic significance, but a minority of…”
Get full text

CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia by Angelova, Evgeniya, Audette, Charlene, Kovtun, Yelena, Daver, Naval, Wang, Sa A, Pierce, Sherry, Konoplev, Sergej N, Khogeer, Haitham, Jorgensen, Jeffrey L, Konopleva, Marina, Zweidler-McKay, Patrick A, Medeiros, L Jeffrey, Kantarjian, Hagop M, Jabbour, Elias J, Khoury, Joseph D

“…The potential of CD123-targeted therapies in acute lymphoblastic leukemia/lymphoma remains largely unexplored. We examined CD123 expression levels in a large…”
Get full text

Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias by Maiti, Abhishek, Franquiz, Miguel J, Ravandi, Farhad, Cortes, Jorge E, Jabbour, Elias J, Sasaki, Koji, Marx, Kayleigh, Daver, Naval G, Kadia, Tapan M, Konopleva, Marina Y, Masarova, Lucia, Borthakur, Gautam, DiNardo, Courtney D, Naqvi, Kiran, Pierce, Sherry, Kantarjian, Hagop M, Short, Nicholas J

“…Philadelphia chromosome-positive (Ph+) advanced leukemias, including acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) in myeloid blast phase…”
Get more information

Risk Factors for Development of and Progression of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome by Corbacioglu, Selim, Jabbour, Elias J., Mohty, Mohamad

“…Veno-occlusive disease, also known as sinusoidal obstruction syndrome (VOD/SOS), is a potentially life-threatening complication of allogeneic or autologous…”
Get full text

Long‐term results of frontline dasatinib in chronic myeloid leukemia by Maiti, Abhishek, Cortes, Jorge E., Patel, Keyur P., Masarova, Lucia, Borthakur, Gautam, Ravandi, Farhad, Verstovsek, Srdan, Ferrajoli, Alessandra, Estrov, Zeev, Garcia‐Manero, Guillermo, Kadia, Tapan M., Nogueras‐González, Graciela M., Skinner, Jeffrey, Poku, Rebecca, DellaSala, Sara, Luthra, Rajyalakshmi, Jabbour, Elias J., O’Brien, Susan, Kantarjian, Hagop M.

“…Background Dasatinib is a second‐generation tyrosine kinase inhibitor that, when used as frontline therapy, produces more and faster cytogenetic and molecular…”
Get full text

Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study by Bose, Prithviraj, Masarova, Lucia, Pemmaraju, Naveen, Bledsoe, Sharon D, Daver, Naval G, Jabbour, Elias J, Kadia, Tapan M, Estrov, Zeev, Kornblau, Steven M, Andreeff, Michael, Jain, Nitin, Cortes, Jorge E, Borthakur, Gautam, Alvarado, Yesid, Richie, Mary Ann, Dobbins, Mackenzie H, McCrackin, Selene A, Zhou, Lingsha, Pierce, Sherry A, Wang, Xuemei, Pike, Allison M, Garcia-Manero, Guillermo, Kantarjian, Hagop M, Verstovsek, Srdan

Get full text

Impact of luteinizing hormone suppression on hematopoietic recovery after intensive chemotherapy in patients with leukemia by Dalle, Iman Abou, Paranal, Ronald, Zarka, Jabra, Paul, Shilpa, Sasaki, Koji, Li, Wen, Ning, Jing, Short, Nicholas J, Ohanian, Maro, Cortes, Jorge E, Jabbour, Elias J, Issa, Ghayas C

“…Treatment of acute leukemia with intensive chemotherapy leads to an increased risk of myelosuppression. Luteinizing hormone (LH) blockade improves…”
Get full text

Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia by Maiti, Abhishek, DiNardo, Courtney D., Wang, Sa A., Jorgensen, Jeffrey, Kadia, Tapan M., Daver, Naval G., Short, Nicholas J., Yilmaz, Musa, Pemmaraju, Naveen, Borthakur, Gautam, Bose, Prithviraj, Issa, Ghayas C., Ferrajoli, Alessandra, Jabbour, Elias J., Jain, Nitin, Garcia-Manero, Guillermo, Ohanian, Maro, Takahashi, Koichi, Montalban-Bravo, Guillermo, Masarova, Lucia, Burger, Jan A., Thompson, Philip A., Verstovsek, Srdan, Sasaki, Koji, Andreeff, Michael, Rausch, Caitlin R., Montalbano, Kathryn S., Pierce, Sherry, Qiao, Wei, Ning, Jing, Kantarjian, Hagop M., Konopleva, Marina Y., Ravandi, Farhad

“…Assessment of measurable residual disease (MRD) provides prognostic information in acute myeloid leukemia (AML). However, the utility of MRD with…”
Get full text

Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia by KONOPLEVA, Marina Y, WALTER, Roland B, HONGBO LU, DEBOSE, Lakiesha, BURGER, Jan A, ANDREEFF, Michael, WENBIN LIU, BAGGERLY, Keith A, KORNBLAU, Steven M, DOYLE, L. Austin, ESTEY, Elihu H, KANTARJIAN, Hagop M, FADERL, Stefan H, JABBOUR, Elias J, ZHIHONG ZENG, BORTHAKUR, Gautam, XUELIN HUANG, KADIA, Tapan M, RUVOLO, Peter P, FELIU, Jennie B

“…Recent studies suggested that AKT activation might confer poor prognosis in acute myelogenous leukemia (AML), providing the rationale for therapeutic targeting…”
Get full text

Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia by Jabbour, Elias J., Kantarjian, Hagop, Eliasson, Lina, Megan Cornelison, A., Marin, David

“…Dramatically improved survival associated with tyrosine kinase inhibitor (TKI) therapy has transformed the disease model for chronic myeloid leukemia (CML) to…”
Get full text

Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors by Sasaki, Koji, Kantarjian, Hagop M., O’Brien, Susan, Ravandi, Farhad, Konopleva, Marina, Borthakur, Gautam, Garcia-Manero, Guillermo, Wierda, William G., Daver, Naval, Ferrajoli, Alessandra, Takahashi, Koichi, Jain, Preetesh, Rios, Mary Beth, Pierce, Sherry A., Jabbour, Elias J., Cortes, Jorge E.

“…Patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs) have near-normal life expectancies. With this comes the possibility…”
Get full text

Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in CRLF2 rearranged and/or JAK driven Philadelphia chromosome-like acute B-cell lymphoblastic leukemia by Zhang, Qi, Shi, Ce, Han, Lina, Jain, Nitin, Roberts, Kathryn G, Ma, Helen, Cai, Tianyu, Cavazos, Antonio, Tabe, Yoko, Jacamo, Rodrigo O, Mu, Hong, Zhao, Yang, Wang, Jing, Wu, Shuo-Chieh, Cao, Fenglin, Zeng, Zhihong, Zhou, Jin, Mi, Yingchang, Jabbour, Elias J, Levine, Ross, Tasian, Sarah K, Mullighan, Charles G, Weinstock, David M, Fruman, David A, Konopleva, Marina

“…Patients with cytokine receptor-like factor 2 rearranged ( -re) subgroup Philadelphia chromosome-like B-cell acute lymphoblastic leukemia (Ph-like B-ALL) have…”
Get full text

Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes by Badar, Talha, Patel, Keyur P, Thompson, Philip A, DiNardo, Courtney, Takahashi, Koichi, Cabrero, Monica, Borthakur, Gautam, Cortes, Jorge, Konopleva, Marina, Kadia, Tapan, Bohannan, Zach, Pierce, Sherry, Jabbour, Elias J, Ravandi, Farhad, Daver, Naval, Luthra, Raja, Kantarjian, Hagop, Garcia-Manero, Guillermo

“…Highlights • Twenty six percent acquired FLT3 or RAS mutation at transformation from MDS to AML. • FLT3 and RAS mutation acquisition were independent predictor…”
Get full text